AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy [Microdose]
Wednesday, February 25, 2026 1 min read
Key Takeaway: Enveric Biosciences has successfully navigated a potential setback as AbbVie withdrew its Post Grant Review petition against one of its key U.S. patents. This patent, which covers halogenated psilocybin derivatives, now faces no remaining challenges. This development is significant for Enveric's strategy in the neuroplastogen sector.
Price reaction · baseline $2.2 (2026-02-24 close) · hit pre-market · 3 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+9.1%
day 1
+5.5%
day 3
+2.3%
Market Sentiment Analysis
POSITIVE FACTORS
AbbVie withdrew its patent challenge, benefiting Enveric.
No remaining challenges against Enveric's key patent.
Strengthens Enveric's position in the neuroplastogen sector.
Full Press Release Details
In a development that could ripple across the fast evolving neuroplastogen sector, Enveric Biosciences announced that a Post Grant Review petition filed against one of its key U.S. patents has been withdrawn. The decision leaves no remaining challenges pending against the company’s U.S. Patent No. 12,138,276, a patent covering halogenated psilocybin derivatives.
Full Article >>
Frequently Asked Questions
What patent challenge was withdrawn by AbbVie?
AbbVie withdrew its Post Grant Review petition against Enveric's U.S. Patent No. 12,138,276.
What does Enveric's patent cover?
The patent covers halogenated psilocybin derivatives.
How does this affect Enveric's strategy?
The withdrawal clears the path for Enveric's psychedelic IP strategy without legal challenges.
What sector is impacted by this development?
This development impacts the fast-evolving neuroplastogen sector.